Introduction: The frequency of thyroid surgery for suspected malignancy but postoperative resulted with benign pathology tends to increase in the worldwide. Therefore, additional preoperative markers are needed to prevent excessive surgery. Neopterin is a new molecule secreted by monocytes and macrophages and indicates the activation of cellular immunity. Therefore it can be used as a marker of immune activation. We aimed to evaluate the diagnostic value of serum neopterin levels to determinedifferentiated thyroid cancers (DTC).
Material and method: This prospectivestudy included 86 patients (67 female and 19 male) who underwent thyroidectomy due to nodular goiter between March 2015 and November 2015. Patients who had overt hyperthyroidism or hypothyroidism andrenal or hepatic dysfunction were excluded from the study. Weight, height and body mass index (BMI) were measured prior the surgery. A fasting blood sample obtained from all study participants prior the surgery to measure serum neopterin levels. Post-thyroidectomy, according to pathology results patients were divided into two groups,as DTC and benign pathology.
Results: Of thesepatients, 39 were diagnosed with DTC and 47 had benign pathology according to postoperative histologic evaluation. There were no significant differences between the two groups in terms of age, weight, height and body mass index. Demographical data and laboratory results are given in the table. There was a positive correlation with neopterin levels and tumor size (r=0.776, P<0.001).
Discussion: Our study indicates that there is a strong association between plasma neopterin levels and DTC. Thus, if it is supported with high volume larger studies, neopterin may be a useful marker forpredicting the DTC preoperatively.
20 - 23 May 2017
European Society of Endocrinology